OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $24.6667.
A number of research analysts have recently issued reports on KIDS shares. Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Truist Financial lifted their target price on shares of OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a research note on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a report on Thursday, January 22nd. Canaccord Genuity Group started coverage on shares of OrthoPediatrics in a research report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price target on the stock. Finally, Wall Street Zen lowered OrthoPediatrics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st.
View Our Latest Report on KIDS
Hedge Funds Weigh In On OrthoPediatrics
OrthoPediatrics Trading Down 2.9%
NASDAQ KIDS opened at $18.67 on Wednesday. The firm has a market capitalization of $468.24 million, a PE ratio of -11.05 and a beta of 1.07. The business’s 50-day moving average price is $17.70 and its two-hundred day moving average price is $18.12. The company has a current ratio of 7.40, a quick ratio of 3.52 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 12 month low of $15.28 and a 12 month high of $26.40.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.68% and a negative net margin of 16.77%.The company had revenue of $61.61 million for the quarter, compared to analyst estimates of $61.27 million. On average, analysts expect that OrthoPediatrics will post -0.93 EPS for the current year.
OrthoPediatrics Company Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Recommended Stories
- Five stocks we like better than OrthoPediatrics
- New Copper-Rich “Kraken” Zone Discovered
- Silver Is the New Oil—And the World’s Running Dry
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- Silver’s squeeze is tightening – opportunity forming
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
